World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Immunology
USA
2026

D-Index & Metrics

Best Scientists

D-Index
177
Citations
205075
World Ranking
660
National Ranking
414

Immunology

D-Index
181
Citations
221850
World Ranking
32
National Ranking
21

Medicine

D-Index
181
Citations
221861
World Ranking
350
National Ranking
219

Jedd D. Wolchok publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Jedd D. Wolchok sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 828 publications — 98th percentile

98% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Jedd D. Wolchok D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Jedd D. Wolchok sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 181 D-Index — 99th percentile

99% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2026 - Research.com Immunology in United States Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Immunology in United States Leader Award
  • 2023 - Research.com Medicine in United States Leader Award
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

Jedd D. Wolchok is affiliated with Cornell University in the United States and focuses primarily on research in medicine, biochemistry, genetics, and molecular biology. Their work is concentrated in oncology, immunology, molecular biology, cancer research, and genetics, reflecting an interdisciplinary approach to understanding and treating cancer.

Their research covers several main topics, including:

  • Cancer Immunotherapy and Biomarkers
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Melanoma and MAPK Pathways
  • Immune cells in cancer
  • Cancer Genomics and Diagnostics
  • Immune Cell Function and Interaction

Jedd D. Wolchok has authored numerous publications with frequent appearance in these venues:

  • Cancer Research
  • Regular and Young Investigator Award Abstracts
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Cancer Cell

They have collaborated extensively with several coauthors in the field, including:

  • Taha Merghoub
  • Sadna Budhu
  • Roberta Zappasodi
  • Michael A. Postow
  • Levi Mangarin

Recent papers authored or coauthored by Jedd D. Wolchok provide insights into cancer immunotherapy and its implementation:

  • Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer, 2023, Nature
  • Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways, 2021, Nature Reviews Clinical Oncology
  • Clinical implications of T cell exhaustion for cancer immunotherapy, 2022, Nature Reviews Clinical Oncology
  • The future of cancer immunotherapy: microenvironment-targeting combinations, 2020, Cell Research
  • Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors, 2021, Immunity

The scientist is recognized as a member of the Association of American Physicians, an acknowledgment of professional contribution to medical science.

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

    Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg

  • Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

    James Larkin;Vanna Chiarion-Sileni;Rene Gonzalez;Jean Jacques Grob

  • Cancer immunotherapy using checkpoint blockade

    Antoni Ribas;Jedd D. Wolchok;Jedd D. Wolchok

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Nivolumab plus Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Harriet Kluger;Margaret K. Callahan;Michael A. Postow

  • Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

    Jedd D. Wolchok;Vanna Chiarion-Sileni;Rene Gonzalez;Piotr Rutkowski

  • Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

    Alexandra Snyder;Vladimir Makarov;Taha Merghoub;Jianda Yuan

  • Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

    Omid Hamid;Caroline Robert;Adil Daud;F. Stephen Hodi

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET

    Héctor Peinado;Maša Alečković;Simon Lavotshkin;Irina Matei

  • Five-year survival with combined nivolumab and ipilimumab in advanced melanoma: New England Journal of Medicine

    J. Larkin;V. Chiarion-Sileni;R. Gonzalez;J.-J. Grob

  • Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

    Julie R. Brahmer;Christina Lacchetti;Bryan J. Schneider;Michael B. Atkins

  • Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber

  • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

    Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov

  • Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

    Michael A. Postow;Jason Chesney;Anna C. Pavlick;Caroline Robert

  • Immune Checkpoint Blockade in Cancer Therapy

    Michael A. Postow;Margaret K. Callahan;Jedd D. Wolchok

  • Antibody therapy of cancer

    Andrew M. Scott;Jedd D. Wolchok;Lloyd J. Old;Lloyd J. Old

  • PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

    Weiping Zou;Jedd D. Wolchok;Lieping Chen

  • iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

    Lesley Seymour;Jan Bogaerts;Andrea Perrone;Robert Ford

  • Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

    Dirk Schadendorf;F. Stephen Hodi;Caroline Robert;Jeffrey S. Weber

Frequent Co-Authors

Taha Merghoub
Taha Merghoub Cornell University
Michael A. Postow
Michael A. Postow Memorial Sloan Kettering Cancer Center
Alan N. Houghton
Alan N. Houghton Memorial Sloan Kettering Cancer Center
Paul B. Chapman
Paul B. Chapman Memorial Sloan Kettering Cancer Center
F. Stephen Hodi
F. Stephen Hodi Harvard University
Jianda Yuan
Jianda Yuan MSD (United States)
Katherine S. Panageas
Katherine S. Panageas Memorial Sloan Kettering Cancer Center
Caroline Robert
Caroline Robert University of Paris-Saclay
James P. Allison
James P. Allison The University of Texas MD Anderson Cancer Center
Matthew D. Hellmann
Matthew D. Hellmann Memorial Sloan Kettering Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Immunology in the USA opens numerous doors in healthcare and research, but many students consider complementary pathways to broaden their expertise. For those interested in advancing clinical skills, transitioning from a Family Nurse Practitioner to a specialized role can be appealing. Exploring how to fnp to acute care np offers insights into more focused patient care opportunities in acute settings.

For individuals without a nursing background eager to enter the field quickly, online options like online bsn programs for non nurses provide a streamlined route. These programs are designed for career changers and emphasize flexibility and accessibility, making them ideal for busy students or professionals.

If you already hold a degree but want to expedite your nursing education, looking into 12-month accelerated nursing programs can be beneficial. These intensive pathways dramatically shorten the time to enter the nursing workforce while maintaining quality education.

Finally, for those ready to fast-track clinical practice, researching the accelerated np programs online reveals accelerated routes to becoming a Nurse Practitioner, combining convenience with rigorous training. Together, these options help shape diverse career trajectories closely linked to Immunology studies.

Best Scientists Citing Jedd D. Wolchok

Trending Scientists

Recently Published Articles